Differential but Competitive Binding of Nogo Protein and Class I Major Histocompatibility Complex (MHCI) to the PIR-B Ectodomain Provides an Inhibition of Cells*

Received for publication, June 23, 2010, and in revised form, May 23, 2011. Published, JBC Papers in Press, June 2, 2011, DOI 10.1074/jbc.M110.157859

Haruka Matsushita†1, Shota Endo†1, Eiji Kobayashi†1, Yuzuru Sakamoto‡1, Keisuke Kobayashi‡, Kohji Kitaguchi‡, Kimiko Kuroki†, Arvid Söderhäll¶, Katsumi Maenaka‡1, Akira Nakamura†, Stephen M. Strittmatter**1, and Toshiyuki Takai‡3

From the †Department of Experimental Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan, the ¶Division of Structural Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan, the ‡Center for General Education, Division of Human Sciences, Tohoku Institute of Technology, Sendai 982-8577, Japan, the §Division of Experimental Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan, the ¶Division of Structural Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan, the ‡Center for Innovative Therapeutic Development Towards the Conquest of Signal Transduction Diseases with Network Medicine, Hokkaido University, Sapporo 060-0812, Japan.

Binding of class I MHC molecules (MHCI) to an inhibitory receptor, PIR-B, expressed on B cells and myeloid cells provides constitutive cellular inhibition, thus ensuring peripheral tolerance. Recent unexpected findings pointed to a novel inhibitory role of PIR-B in neurite regeneration through binding to three axonal outgrowth inhibitors of myelin, including Nogo. Thus, it becomes interesting to determine whether the actions of the inhibitory myelin proteins and MHCI could coexist independently or be mutually exclusive as to the PIR-B-mediated immune and neural cell inhibition. Here, we present data supporting the competition of Nogo- and MHCI-mediated inhibition where they coexist. Kinetic analyses of Nogo and MHCI binding to the whole or a part of the recombinant PIR-B ectodomain revealed that PIR-B binds with higher affinity to Nogo than MHCI and that the MHCI binding only occurred with the N-terminal domains of PIR-B, whereas Nogo binding occurred with either the N- or C-terminal ectodomains. Importantly, kinetic tests indicated that the binding to PIR-B of Nogo and MHCI was competitive. Both endogenous and exogenous Nogo intensified the PIR-B-mediated suppression of interleukin-6 release from lipopolysaccharide-stimulated wild-type, but not PIR-B-deficient, cultured mast cells, indicating that PIR-B mediates Nogo-induced inhibition. Thus, we propose a novel mechanism by which PIR-B-mediated regulation is achieved differentially but competitively via MHCI and Nogo in cells of the immune system.

PIR-B (paired Ig-like receptor-B), expressed on murine myeloid lineage cells, B cells, and prethymic stage T cells is an immunoregulatory cell-surface receptor (1–5), whose physiological ligand in the immune system has been identified as class I MHC molecules (MHCI; also known as class I H-2 and HLA in mice and humans, respectively) (6). Because MHCI are expressed ubiquitously, the binding to MHCI causes PIR-B to deliver a constitutive inhibitory signal via recruitment of tyrosine phosphatase, Src homology 2 domain-containing tyrosine phosphatase-1 (7–9), whose substrates are critical cytosolic signaling molecules such as Bruton’s tyrosine kinase (10). Similar to other stimulatory and inhibitory receptor pairs with shared ligand-binding specificities (11), PIR-B expression usually takes place concomitantly with that of the activating-type isoform PIR-A although the physiological role of PIR-A in the immune system remains largely unknown.

Recent unexpected findings have revealed additional inhibitory roles of PIR-B in synaptic plasticity (12) and axonal regeneration (13) in the neuronal system. In mice lacking functional PIR-B, the cortical ocular dominance plasticity is more robust, indicating that PIR-B functions to limit the extent of experience-dependent plasticity in the visual cortex and suggesting that it may function broadly to stabilize neuronal circuits (12). Surprisingly, it has also been reported (13) that PIR-B can bind to three axonal outgrowth inhibitory proteins in oligodendrocytes, i.e. neurite outgrowth inhibitor protein (Nogo) (14), myelin-associated glycoprotein (MAG) (15, 16), and oligodendrocyte myelin glycoprotein (OMgp) (17), like the Nogo receptor does (18, 19). Interfering with PIR-B activity, either with antibodies or by genetic deletion of the cytoplasmic portion of PIR-B, partially reverses the neurite inhibition by Nogo, MAG, and OMgp, implying that PIR-B mediates the regeneration blocking of axons (13).

Given the two kinds of physiological ligands for PIR-B, i.e. MHCI and neurite outgrowth inhibitor proteins, we were
immediately interested in determining how differently PIR-B binds to these immunomodulators, examining simultaneously whether or not PIR-A can also bind to the myelin-associated inhibitor proteins in addition to MHCI.

**EXPERIMENTAL PROCEDURES**

**Preparation of Recombinant PIR Domains—PIR-B, like PIR-A, is a type I transmembrane glycoprotein with a ligand-binding ectodomain structure composed of six Ig-like domains (D1 to D6, from the N to the C terminus). Recombinant proteins for D1–D6, D1D2, and D3–D6 of PIR-B and PIR-A were prepared according to the following procedures. PIR-B domain fragment DNAs were amplified from a C57BL/10-derived whole-length PIR-B cDNA inserted into the pcEXV-3 vector as a template by using following primers: PIR-B (D1–D6), 5'-CAGGTACGGGGTCTCCCTCCTAGG-3' and 5'-ATGATATCTGAGACTGTGAGCTC-3'; PIR-B (D1D2), 5'-AGGATATCTGaGGACGAGCTC-3' and 5'-CAGGTACGGGGTCTCCCTCCTAGG-3'; and PIR-B (D3-D6), 5'-TGGGTACCGGTAAACTCCAAAAA-3' and 5'-ATGATATCTGAGACTGTGAGCTC-3'. Each DNA fragment was inserted into pHLsec vector or pSecTag2-b harboring Fc portion DNA of BALB/c IgG3. The resultant plasmids were transfected to 293-F (Invitrogen) as a host cell to express the recombinant proteins. PIR-A4 D1–D6 fragment DNAs were amplified from C57BL/6 spleen cDNA with the primers 5'-TCTAGAGATGCCATGTCCCTCCCTAAGCCTATCCTCGACC-3' and 5'-TCTAGAATGATTAGTTCCACCTGCTCAGG-3'. The fragment was inserted into pcDNA3.1 Zeo(+)(Invitrogen). The resultant plasmid was further digested with BglII and NgoMIV to obtain CMV promoter-inserted poly(A) site fragment and ligated into pSV2-dhfr (ATCC) as described previously (20). PIR-A4 D1D2 and D3–D6 DNA fragments were amplified from PIR-A4 D1–D6 DNA-inserted pcDNA3.1 Zeo(+) vector as a template with following primers: PIR-A4 (D1D2), 5'-CCATGGGCGCTCCCTAAAGCTACCTCCCTC-3' and 5'-CCATGGGCGCTCCCTAAAGCTACCTCCCTC-3'; PIR-A4 (D3–D6), 5'-GATATCAGGATCTCCTCCAAACACCACT-3' and 5'-GATATCAGGATCTCCTCCAAACACCACT-3'; and PIR-A4 (D3–D6), 5'-GATATCAGGATCTCCTCCAAACACCACT-3'. The DNA fragments were inserted into pEX-hlg1e3-Fc2 vector (InvivoGen, San Diego, CA). For the expression of PIR-A4 D1–D6 monomer, the plasmid was transfected to the DG44 cell (Invitrogen) and applied for gene amplification with methotrexate (Sigma) as described previously (20). For the expression of PIR-A4 D1D2 and D3–D6 Fc fusion protein, the plasmids were transfected to CHO-K1 cells. Purification of recombinant proteins was performed by affinity purification with HiTrap Protein A (GE Healthcare) or D1D2-specific anti-PIR-A/B (6C1, a generous gift from Dr. H. Kubagawa, University of Alabama at Birmingham, and Dr. M. D. Cooper, Emory University, Atlanta, GA)—immobilized affinity column.

**Surface Plasmon Resonance (SPR) Analysis of PIR Domain Binding to MHCI, Nogo-66, and MAG**—For the SPR analysis of PIR, the following recombinant proteins were used. Biotinylated H-2Kβ monomer (loaded with a tyrosinase-related protein 2 peptide, SVYDFFVWL and coupled with mouse β2-m, B) (Sanquin, Amsterdam, Netherlands), H-2Dα monomer (loaded with an influenza virus nucleoprotein F5 peptide, ASNENMDAM, and coupled with mouse β2-m, B) (Sanquin), HLA-G monomer (loaded with a histone H2A derived peptide, RIIPRHLQL; kind gift from Dr. Maenaka, Kyushu University), Nogo-66-Fc (recombinant rat Nogo-A/Fc amino acids 1026–1090, R&D Systems, Minneapolis, MN) and MAG-Fc (recombinant rat MAG/Fc, R&D Systems). SPR analysis was performed with a BIAcore 2000 (BIAcore, Uppsala, Sweden) as essentially described elsewhere (6). In brief, ligand proteins were immobilized at 1500–2500 response units on research-grade CM5 chips (BIAcore) through covalently coupled streptavidin. Analyte proteins, after buffer exchange to HBS-EP buffer comprising 10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, and 0.005% Surfactant P20 (BIAcore), were injected over the immobilized flow cells at 25 °C. The binding interactions were assayed at 20 μl/min. The binding responses with various concentrations were subtracted from the nonspecific responses to an empty flow cell. Kinetic constants were calculated from sensorgram data with the BIA evaluation program (version 3.0.2; BIAcore). KD values were obtained using the bivalent analyte model for Fc fusion proteins or determined from the equilibrium binding data fit to a 1:1 binding model for monomer proteins.

**Mice—C57BL/6 mice were purchased from Charles River Japan Inc. (Yokohama, Japan). Pirb−/− mice were generated (21) and back-crossed with C57BL/6 for twelve generations. β2-microglobulin-deficient (B2m−/−) mice were purchased from The Jackson Laboratory (Bar Harbor, MA). Nogo-A/B-deficient mice were developed by Stephen M. Strittmatter (Yale University) (22). Mice were maintained and bred in the Animal Facility of The Institute of Development, Aging and Cancer, Tohoku University, an environmentally controlled and specific pathogen-free facility, according to the guidelines for experimental animals defined by the university, and the animal protocols were reviewed and approved by the Animal Studies Committee of the university. All experiments were performed on 8-to-14-week-old age-matched male and female mice.

**Mast Cell Culture**—For preparation of bone marrow (BM)-derived cultured mast cells (BMMCs), bone marrow cells were obtained from both hind limbs (femur and tibia) of 8-week-old female C57BL/6 mice. After lysing the erythrocytes with lysis buffer (0.144 M ammonium chloride solution), BM cells were suspended at a density of 5×10⁶ cells/ml in RPMI 1640 medium (Sigma-Aldrich), supplemented with 10% FCS, 50 international units/ml penicillin, 50 μg/ml streptomycin, 50 μM 2-mercaptoethanol, 1 mM sodium pyruvate, 0.1 mM minimum essential medium nonessential amino acids solution, and 5 ng/ml mouse rIL-3 (R&D Systems), and then incubated at 37 °C under a humidified atmosphere of 5% CO₂ and 95% air. The BM-derived nonadherent cells were transferred every 6–7 days to new culture flasks at a density of 5×10⁶ cells/ml over a 4-to-10-week culture period. Over 90% of the cells were identified as immature mast cells at 4 weeks after initiation of the culture (23) and were designated as BMMCs.

**Confocal Microscopy Analysis**—Confocal laser-scanning microscopy of BMMCs was performed with Alexa Fluor®-546-conjugated (Invitrogen) Nogo-66-Fc (R&D Systems), Alexa 488-conjugated anti-PIR-A/B (6C1), and Alexa 647-conjugated anti-H-2Kβ/Dα (clone 28-6-8). All of these mAbs were directly labeled by an Alexa Fluor 488, 546, or 647 monoclonal labeling
Alexa Fluor 546-conjugated Nogo-66-Fc in the presence or absence of LPS (K12; InvivoGen) in the presence of 5 μM NogoA-Fc chimeric protein (R&D Systems) or murine recombinant IgG2a-Fc (R&D Systems). Culture supernatants were collected 16 h after stimulation. The amount of IL-6 produced was determined with a mouse IL-6 ELISA Max Set standardized relative to the highest peak (y axis). The correlation coefficient was calculated on a pixel-by-pixel basis according to Equation 1,

$$\sigma_{xy} = \frac{\sum (x - \bar{x})(y - \bar{y})}{\sqrt{\sum (x - \bar{x})^2 \sum (y - \bar{y})^2}}$$  \hspace{1cm} (Eq. 1)$$

where $x$ and $y$ are the intensities of the green and red channels in a pixel, and $\bar{x}$ and $\bar{y}$ are the average intensities of the green and red channels within the region of interest. The correlation coefficient theoretically ranges from $-1$ to $1$, where $1$ indicates perfect overlap, $0$ indicates random distribution, and $-1$ indicates avoidance.

**Competition Assay of Nogo-66-Fc/HLA-G Binding to PIR-B—**

5 × 10⁵ cells/sample of PIR-B-transfected E.G7 cells (E.G7-PirB) (20) were stained with graded concentration (0 to 5 μM) of Alexa Fluor 546-conjugated Nogo-66-Fc in the presence or absence of a fixed concentration (7 μM) of recombinant HLA-C monomer for 40 min at 37 °C. The samples were then washed three times with PBS and suspended in 100 μl of PBS. Ten μl aliquot of the suspensions was mounted on a water-repellent and aminopropylsilanes-coated glass slide (TF240A4, Matsunami Glass Ind., Ltd.), incubated for 15 min at room temperature, fixed with 4% paraformaldehyde, washed three times with PBS, and mounted with Fluoromount® (Dignostic BioSystems, Pleasanton, CA) and coverglass. The slides were scanned and fluorescence intensity of the images was measured with Fluoview FV1000 confocal laser scanning microscope (Olympus). Mean fluorescence intensity of each concentration was calculated from 16 images of two replicate wells.

**Measurement of Cytokine IL-6—**BMMCs cultured at 2 × 10⁶ cells/ml in complete RPMI medium containing 10% FCS supplemented with 5 ng/ml IL-3 (PeproTech, Hamburg, Germany) in 96-well flat plates (Corning, Lowell, MA) were stimulated with 0–1000 ng/ml LPS (K12; InvivoGen) in the presence of 5 μg/ml NogoA-Fc chimeric protein (R&D Systems) or murine recombinant IgG2a-Fc (R&D Systems). Culture supernatants were collected 16 h after stimulation. The amount of IL-6 produced was determined with a mouse IL-6 ELISA Max Set standard (BioLegend, San Diego, CA).

**Reverse Transcription-PCR—**For RT-PCR analysis of mRNAs for Nogo isoforms (NogoA, B1, and B2), MAG, and OMgp in immune cells, total RNA was extracted with an RNeasy Mini Kit (Qiagen, Valencia, CA) from brain samples, and splenic CD19+ B cells and Thy-1+ T cells isolated from splenocytes with a magnetic-activated cell sorter (Miltenyi Biotech, Bergisch Gladbach, Germany), BM-derived GM-CSF-induced cultured DCs, BM-derived M-CSF-induced cultured macrophages, and BM-derived IL-3-induced BMMCs: all samples were from C57BL/6 mice. First-strand cDNA was synthesized with oligo(dT) primer (TaKaRa Biotechnology, Ohtsu, Japan), and the cDNA was amplified with the following target-specific primers: NogoA (forward), 5’-GCAAGGCTGAATAAACCTCAG-3’; NogoB1 (forward), 5’-GCAAGGGCTCAGGGCTCAGTG-3’; NogoB2 (forward), 5’-GCTCTCTCTGCTGACATCTGAG-3’ and the common reverse primer for NogoA/B1/B2, 5’-GTTCAATGACCAAGACGCA-3’; MAG, 5’-CCATGGGCCAATCGGTCGCTG-3’ and 5’-CCATGGCAGAGCCATTGGCCAC-3’; OMgp, 5’-ACTCTTAAGCCTTTACTGATAG-3’ and 5’-AGTGTTTCATCGCAGTGGTT-3’; and hypoxanthine phosphoribosyltransferase, 5’-TGATCAGTCAACGGGGACA-3’ and 5’-TGATCAGTCAACGGGGACA-3’ and 5’-TTCTGAGAGTTTGGCCACAC-3’. Thirty cycles of PCR were carried out with Ex-TaqDNA polymerase (TaKaRa Biotechnology) with denaturation at 95 °C for 30 s, annealing at 60 °C for 30 s, and elongation at 72 °C for 60 s.

**Statistical Analysis—**Statistical analyses were performed using two-way analysis of variance or Student’s t test. $p < 0.05$ was considered as being statistically significant.

**RESULTS**

**PIR-B D1D2 Binds to H-2 Molecules—**We prepared recombinant ectodomains of PIR-B, i.e. the whole D1–D6 protein, or the N-terminal D1D2 and C-terminal D3–D6 separately (supplemental “Results” and Fig. S1). These recombinant proteins, at various concentrations, were examined for their binding to a recombinant H-2 α chain β₂m complex fixed on a sensor chip for SPR analysis (Fig. 1). As shown in the sensorgrams for D1-D6 (Fig. 1A), D1D2 (Fig. 1B), and D3-D6 (Fig. 1C), binding of the PIR-B domains to H-2Db was detected for D1-D6
Nogo Augments Immunosuppression by PIR-B

(\(K_D = 4.0 \pm 1.9 \, \mu M\), Table 1) and D1D2 (\(K_D = 29 \pm 5 \, \mu M\)), but not for D3-D6. Thus, we concluded that the binding site for the H-2 \(\alpha\) chain-\(\beta_2m\) complex resides exclusively in D1D2 of PIR-B.

**TABLE 1**

| Recombinant ectodomain | \(K_D^{x}\) H-2D\(\alpha\) | HLA-G | Nogo-66 |
|-------------------------|-----------------|--------|--------|
| PIR-B                   |                 |        |        |
| D1–D6                  | 4.0 ± 1.9\(^x\) | 2.4 ± 0.7 (3) | 0.57\(^x\) (1) |
| D1D2                   | 29 ± 5 (3)      | 24 ± 4 (3)  | 8.5 (1) |
| D3–D6                  | NB\(^x\) (1)     | ND\(^x\) | 0.80 (1) |
| PIR-A                   |                 |        |        |
| D1–D6                  | + (1)           | ND     | 6.9 (2) |
| D1D2                   | ND              | ND     | NB (1) |
| D3–D6                  | ND              | ND     | 4.3 (2) |

\(^x\) Recombinant extracellular Ig-like domains of PIR (see supplemental Fig. S1A).

\(^{a}\) Affinity was determined from the binding data fit to a bivalent analyte model for Fc fusion proteins or to a 1:1 binding model for fusion proteins without Fc.

\(^{b}\) Affinity values were determined from the numbers of response units with various concentrations of analytes. Data are presented as the value(s) for either a single determination, the means for two different experiments, or the means ± S.D. for three to four different experiments, the number of experiments are given in parentheses. The \(K_D\) value of PIR-B–H-2D\(\alpha\) binding was larger than that reported previously (6), possibly due partly to the fact that in our previous SPR analysis, we employed the H-2 \(\alpha\) chain complexed with human \(\beta_2m\) to ensure the stability of the complex, and we calculated the \(K_D\) at lower concentrations of analyte than the current analysis.

\(^{c}\) The \(K_D\) value is larger than that reported previously (13), possibly due to the difference in the assay methods: Atwal et al. (13) employed an enzyme-linked immunosorbent assay.

\(^{d}\) NB, no binding detected.

\(^{e}\) ND, not done.

\(^{f}\) Binding was detected with a fixed concentration of an analyte.

PIR-B Can also Bind to Either \(\beta_2m\)-free H-2 or to Human HLA-G—Recent reports have demonstrated that a human PIR-B ortholog, LILRB1 (leukocyte Ig-like receptor), does not recognize the \(\beta_2m\)-free form of HLA-B27 or HLA-G, but that LILRB2 does (25, 26). This arises from differences in a limited number of amino acid residues (25, 26). Also, in the HLA-B27 transgenic rodent model, HLA-B27 heavy chain homodimers become ligands for PIR (27). These preceding observations suggest that PIR-B could also bind to the \(\beta_2m\)-free form of MHC-I. Thus, we attempted to directly measure the PIR-B binding to the \(\beta_2m\)-free chain of H-2D\(\beta\), prepared by acid treatment of the whole H-2 complex immobilized on a sensor chip. Successful removal of \(\beta_2m\) probably along with a peptide from the H-2 heavy chain was confirmed by the fact that the H-2 on the sensor chip was not recognizable with anti-\(\beta_2m\) polyclonal antibodies (data not shown). Our SPR analysis revealed that PIR-B D1D2 was able to bind to the \(\beta_2m\)-free chain of H-2D\(\beta\) (Fig. 2A) and even to a human nonclassical (or less polymorphic) MHC-I, HLA-G (Fig. 2, B and C), indicating that PIR-B possesses broad binding specificity, binding to the whole MHC-I complex, \(\beta_2m\) (6), and the MHC-I heavy chain lacking \(\beta_2m\) and a peptide, and even to human MHC-I.

**PIR-B D1-D6 Is Flexible**—Although PIR-B D1D2 plays a major role in MHC-I binding, PIR-B D3-D6 may play a role by supporting the MHC-I binding by D1D2, such stabilization of the steric structure of D1D2. Also, the D3–D6 region together with D1D2 may be flexible under physiological conditions,

![FIGURE 2. SPR analysis of the binding of recombinant PIR-B domains to \(\beta_2m\)-free H-2D\(\beta\) and HLA-G. A, representative SPR profiles of the binding of D1D2, at various concentrations, to the acid-treated \(\beta_2m\)-free H-2D\(\beta\) (green), nontreated H-2D\(\beta\) (red), and to an empty chip (blue). The H-2 protein was immobilized on sensor chips. B and C, representative SPR profiles of the binding of D1–D6 (B) and D1D2 (C), at various concentrations, to the HLA-G protein. RU, response units.](image-url)
which might make the receptor easily accessible to MHCI expressed on the same cell (in cis) (24) or on different cells (in trans) (20, 28). Binding of MHCI to the terminal ectodomain of PIR-B and a flexible nature of the ectodomain were supported by our data from protein tomography analysis of PIR-B ectodomain and MHCI in aqueous solution (supplemental “Results” and Fig. S2).

PIR-A Binds to MHCI with Less Efficiency than PIR-B—Regarding PIR-A binding to MHCI, although our previous study demonstrated that MHCI tetramer binds to PIR-A on Pirb−/− macrophages (6), SPR measurement of the binding of PIR-A to MHCI remains to be determined. Therefore, we also generated recombinant PIR-A D1D2, D3–D6, and D1–D6 (supplemental Fig. S1). Due to an unknown reason, we could not obtain enough amounts of the recombinant PIR-A proteins to determine the affinity values. Instead, we compared the binding response to MHCI between PIR-A and PIR-B. As shown in Fig. 3, PIR-A D1–D6 binds to the whole H-2 complex with a lesser efficiency than PIR-B D1–D6.

PIR-B and PIR-A Bind to Nogo and MAG—We next attempted to determine the binding kinetics of Nogo and MAG as to PIR-B. We also examined whether PIR-A binds to these axonal outgrowth inhibitors. Our SPR analysis of PIR-B D1–D6 binding to Nogo-66, a 66-amino acid peptide of Nogo essential for binding to the Nogo receptor (18, 19),

![Graphs showing SPR analysis of PIR-A binding to H-2 and Nogo-66](image)

Nogo Augments Immunosuppression by PIR-B

JULY 22, 2011 • VOLUME 286 • NUMBER 29
JOURNAL OF BIOLOGICAL CHEMISTRY
25743
revealed that the binding affinity was higher ($K_D = 0.57 \mu M$, Fig. 4A) than that in the case of MHCI (Fig. 1A and Table 1). Interestingly, similar analysis revealed that PIR-A D1–D6 can also bind to Nogo-66 (Fig. 4D), although its affinity is much lower ($K_D = 6.9 \mu M$, mean of two separate determinations, Table 1) than that of PIR-B. Additionally, we detected the binding of PIR-B D1-D6 to MAG (Fig. 5A), but the affinity was much lower ($K_D = 33 \mu M$) than that of PIR-B as to Nogo-66. PIR-A D1-D6 binding to MAG was detected, and the affinity seemed to be higher than that in the case of PIR-B (Fig. 5B).

Both D1D2 and D3–D6 of PIR-B Bind to Nogo—Given that PIR-B and PIR-A bind to Nogo-66, we were interested in dissecting the binding domains. Again, D1D2 and D3–D6 of PIR-B and PIR-A were subjected to SPR analysis of binding to Nogo-66. We found that both D1D2 and D3–D6 of PIR-B can bind to Nogo-66 (Fig. 4B, C). The affinity of D1D2 or D3–D6 to Nogo-66 ($K_D = 8.5 \mu M$ or 0.80 $\mu M$, respectively) was lower than, or roughly comparable with, that of D1–D6 (0.57 $\mu M$, Fig. 4A and Table 1), respectively. On the other hand, PIR-A D3–D6 was found to bind to Nogo-66 with affinity ($K_D = 4.3 \mu M$, mean of two separate determinations, Fig. 4F and Table 1) comparable with that of D1–D6 of PIR-A ($K_D = 6.9 \mu M$, mean of two separate determinations, Fig. 4D and Table 1). We failed to detect, however, binding activity of PIR-A D1D2 as to Nogo-66 (Fig. 4E). These results indicate that, unlike MHCI binding, both D1D2 and D3–D6 of PIR-B can bind to Nogo-66, and that, unlike PIR-B binding, PIR-A binding to Nogo-66 only occurs with D3–D6.

The differential binding of MHCI and Nogo to PIR-B shown above suggests that PIR-B harbors only one binding region for MHCI, D1D2, whereas it harbors two or more separate binding regions for Nogo-66. MHCI is a 57-kDa protein complex. On the other hand, a dimeric Nogo-66, which is a critical portion of Nogo-66–Fc chimera employed as a ligand for our SPR analysis, is 16 kDa. Because the molecular masses of PIR-B D1D2 and D3–D6 are 22 and 44 kDa, respectively, each of these portions of PIR-B is sufficiently large enough to accept one or more dimeric Nogo-66 peptides. Therefore, our next question was how much the binding site(s) for Nogo-66 in PIR-B overlap(s) with that of MHCI, or if these two ligands compete with each other for binding.

**Binding of Nogo and MHCI to PIR-B Is Competitive**—We initially anticipated that PIR-B is able to bind simultaneously to MHCI and Nogo-66. In partial support of this, our confocal laser microscopic analysis of intrinsically expressed PIR-B and MHCI on BMMCs and the extrinsically added Nogo-66–Fc recombinant protein bound to the cells revealed that these three molecules co-localized partly, but not solely, on the same cell surface (supplemental Fig. S3). However, this result does not verify a formation of a ternary complex of Nogo-PIR-B-MHCI. Therefore, we next examined a potential competition between Nogo and MHCI to PIR-B by SPR analysis (Fig. 6A). H-2K$^d$- or H-2D$^d$-immobilized sensor chip was subjected for binding to PIR-B D1-D6 in the presence or absence of fixed concentration (5 $\mu M$) of Nogo-66–Fc. A cell-based competitive binding assay of PIR-B and Nogo-66-Fc in the presence or absence of HLA-G. PIR-B-transfected E.G7 cells were stained with Alexa Fluor 546-conjugated Nogo-66–Fc in the presence or absence of a fixed concentration (7 $\mu M$) of recombiant HLA-G. Acquisition of the image and measurement of the fluorescent intensity were performed under a Fluoview FV1000 confocal laser scanning microscope. Each point represents the mean ± S.E. from 16 images of two replicate wells. MFI, mean fluorescence intensity; AU, arbitrary unit; RU, response units. 
We found that in the presence of HLA-G, Nogo-66 binding to the cells was inhibited. These results indicate that Nogo-66 and MHCI are competitive in their binding to PIR-B. Our results also suggest that PIR-B on cell surface can exert its regulatory function differentially but competitively through endogenous Nogo and MHCI. This notion is examined below.

**Endogenous Nogo and MHCI Induce PIR-B-mediated Inhibition of IL-6 Release from LPS-stimulated Mast Cells**—We stimulated BMMCs from wild-type C57BL/6 or Pirb−/−, B2m−/−, or NogoA/B-deficient mice with various concentrations of LPS in the presence of Nogo-66-Fc or control Fc proteins. After 16 h (A) or 10 h (B), the culture supernatants were collected and subjected to IL-6 measurement by ELISA. Data are shown as mean of triplicate samples ± S.D. Representative data for two experiments with similar results are shown (*, p < 0.05; **, p < 0.01). In A, the IL-6 release from wild-type mast cells was slightly but significantly inhibited by Nogo-66 at some LPS concentrations, whereas such inhibition was not observed in the absence of PIR-B. Note that with PIR-B deficiency, the IL-6 release was higher than from the cells with PIR-B, indicating that PIR-B inhibits the mast cell response. In B, although the observed Nogo-66-mediated suppression in wild type and B2m−/− cells was statistically significant only at 1 μg/ml LPS, its suppression was much more significant in cells with no intrinsic NogoA/B. Note again that with B2m and NogoA/B deficiencies, the IL-6 release was higher than from wild type cells, indicating that endogenous β2m and NogoA/B inhibit mast cell response.

**Fig. 7.** Nogo augments PIR-B-mediated suppression of IL-6 release from cultured mast cells stimulated with LPS. Bone marrow-derived cultured mast cells from C57BL/6 (wild type), Pirb−/−, B2m−/−, or NogoA/B-deficient mice were stimulated with various concentrations of LPS in the presence of Nogo-66-Fc or control Fc proteins. After 16 h (A) or 10 h (B), the culture supernatants were collected and subjected to IL-6 measurement by ELISA. Data are shown as mean of triplicate samples ± S.D. Representative data for two experiments with similar results are shown (*, p < 0.05; **, p < 0.01). In A, the IL-6 release from wild-type mast cells was slightly but significantly inhibited by Nogo-66 at some LPS concentrations, whereas such inhibition was not observed in the absence of PIR-B. Note that with PIR-B deficiency, the IL-6 release was higher than from the cells with PIR-B, indicating that PIR-B inhibits the mast cell response. In B, although the observed Nogo-66-mediated suppression in wild type and B2m−/− cells was statistically significant only at 1 μg/ml LPS, its suppression was much more significant in cells with no intrinsic NogoA/B. Note again that with B2m and NogoA/B deficiencies, the IL-6 release was higher than from wild type cells, indicating that endogenous β2m and NogoA/B inhibit mast cell response.
that intrinsic NogoA/B in BMMCs play a role in the suppression.

**DISCUSSION**

In this study, we have shown for the first time that MHCI and Nogo bind to PIR-B differentially in terms of the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s). Interestingly, the binding affinities and the binding site(s).

**REFERENCES**

1. Hayami, K., Fukuta, D., Nishikawa, Y., Yamashita, Y., Inui, M., Ohyama, Y., Hikida, M., Ohmori, H., and Takai, T. (1997) *J. Biol. Chem.* **272**, 7320–7327.
2. Kubagawa, H., Burrows, P. D., and Cooper, M. D. (1997) *Proc. Natl. Acad. Sci. U.S.A.* **94**, 5261–5266.
3. Kubagawa, H., Chen, C. C., Ho, L. H., Shimada, T. S., Gartland, L., Mashburn, C., Uehara, T., Ravetch, J. V., and Cooper, M. D. (1999) *J. Exp. Med.* **189**, 309–318.
4. Masuda, K., Kubagawa, H., Ikawa, T., Chen, C. C., Kakugawa, K., Hattori, M., Kageyama, R., Cooper, M. D., Miinato, N., Katsura, Y., and Kawamoto, H. (2005) *EMBO J.* **24**, 4052–4060.
5. Takai, T. (2005) *Immunology* **115**, 433–440.
6. Nakamura, A., Kobayashi, E., and Takai, T. (2004) *Nat. Immunol.* **5**, 623–629.
7. Bléry, M., Kubagawa, H., Chen, C. C., Vély, F., Cooper, M. D., and Vivier, E. (1998) *Proc. Natl. Acad. Sci. U.S.A.* **95**, 2446–2451.
8. Maeda, A., Kurosaki, M., Ono, M., Takai, T., and Kurosaki, T. (1998) *J. Exp. Med.* **185**, 1355–1360.
9. Ho, L. H., Uehara, T., Chen, C. C., Kubagawa, H., and Cooper, M. D. (1999) *Proc. Natl. Acad. Sci. U.S.A.* **96**, 15086–15090.
10. Maeda, A., Scharenberg, A. M., Tsukada, S., Bolen, J. B., Kinet, J. P., and Kurosaki, T. (1999) *Oncogene* **18**, 2291–2297.
11. Colonna, M., and Samardis, I. (1995) *Science* **268**, 405–408.
12. Syken, J., Grandpre, T., Kanold, P. O., and Shatz, C. J. (2006) *Science* **313**, 1795–1800.
13. Atwal, J. K., Pinkston-Gosse, J., Syken, J., Sawicki, S., Wu, Y., Shatz, C., and Tessier-Lavigne, M. (2008) *Science* **322**, 967–970.
14. Prinjha, R., Moore, S. E., Vinson, M., Blake, S., Morrow, R., Christie, G., Michalovich, D., Simmons, D. L., and Walsh, F. S. (2000) *Nature* **403**, 383–384.
15. Domeniconi, M., Cao, Z., Spencer, T., Sivasankaran, R., Wang, K., Nikulina, E., Kimura, N., Cai, H., Deng, K., Gao, Y., He, Z., and Filbin, M. (2002) *Neurov* **35**, 283–290.
16. Liu, B. P., Fournier, A., Grandpre, T., and Strittmatter, S. M. (2002) *Science* **297**, 1190–1193.
17. Wang, K. C., Koprivica, V., Kim, J. A., Sivasankaran, R., Guo, Y., Neve, R. L., and He, Z. (2002) *Nature* **417**, 941–944.
18. Fournier, A. E., Grandpre, T., and Strittmatter, S. M. (2001) *Nature* **409**, 341–346.
19. McCge, A. W., and Strittmatter, S. M. (2003) *Trends Neurosci.* **26**, 193–198.
20. Endo, S., Sakamoto, Y., Kobayashi, E., Nakamura, A., and Takai, T. (2008) *Proc. Natl. Acad. Sci. U.S.A.* **105**, 14515–14520.
21. Ujike, A., Takeda, K., Nakamura, A., Ebihara, S., Akiyama, K., and Takai, T. (2002) *Nat. Immunol.* **3**, 542–548.
22. Kim, J. E., Li, S., Grandpré, T., Qiu, D., and Strittmatter, S. M. (2003) *Neuron* **38**, 187–199.
23. Kanehira, M., Kaifu, T., Maya, K., Kaji, M., Nakamura, A., Obinata, M., and Takai, T. (2006) *J. Biochem.* **140**, 211–220.
24. Masuda, A., Nakamura, A., Maeda, T., Sakamoto, Y., and Takai, T. (2007) *J. Exp. Med.* **204**, 907–920.
25. Shiroishi, M., Kuroki, K., Rasubala, L., Tsumoto, K., Kumagai, I., Ku-
rimoto, E., Kato, K., Kohda, D., and Maenaka, K. (2006) Proc. Natl. Acad. Sci. U.S.A. **103**, 16412–16417
26. Allen, R. L., Raine, T., Haude, A., Trowsdale, J., and Wilson, M. J. (2001) *J. Immunol.* **167**, 5543–5547
27. Kollinberger, S., Bird, L. A., Roddis, M., Hacquard-Bouder, C., Kubagawa, H., Bodmer, H. C., Breban, M., McMichael, A. J., and Bowness, P. (2004) *J. Immunol.* **173**, 1699–1710
28. Shatz, C. J. (2009) *Neuron* **64**, 40–45
29. Acevedo, L., Yu, J., Erdjument-Bromage, H., Miao, R. Q., Kim, J. E., Fulton, D., Tempst, P., Strittmatter, S. M., and Sessa, W. C. (2004) *Nat. Med.* **10**, 382–388
30. Miao, R. Q., Gao, Y., Harrison, K. D., Prendergast, J., Acevedo, L. M., Yu, J., Hu, F., Strittmatter, S. M., and Sessa, W. C. (2006) Proc. Natl. Acad. Sci. U.S.A. **103**, 10997–11002
31. Datwani, A., McConnell, M. J., Kanold, P. O., Micheva, K. D., Busse, B., Shamloo, M., Smith, S. J., and Shatz, C. J. (2009) *Neuron* **64**, 463–470
32. Boulanger, L. M. (2009) *Neuron* **64**, 93–109
33. Maeda, A., Kurosaki, M., and Kurosaki, T. (1998) *J. Exp. Med.* **188**, 991–995
34. Taylor, L. S., and McVicar, D. W. (1999) *Blood* **94**, 1790–1796

**Nogo Augments Immunosuppression by PIR-B**